Abstract
Early attempts to use high-dose chemotherapy technology in order to improve the effect of nitrosourea on high-grade gliomas resulted in minimal benefit as well as in severe toxicity. Since then, other drugs have been applied in conjunction with either autologous bone marrow or peripheral blood stem cells, including thiotepa, etoposide, melphalan, cyclophosphamide, and busulfan. The data suggest benefit in recurrent primitive neuroectodermal tumors (PNET), in newly diagnosed young children with PNET and possibly in young children with newly diagnosed ependymoma, as a strategy not only to improve tumor-free survival but also to avoid exposure of the young brain to irradiation. In other tumors such as recurrent ependymoma and newly diagnosed or recurrent brain stem glioma, high-dose chemotherapy remains ineffective. New protocols under evaluation include new agents, multiple cycles of high-dose chemotherapy and allogeneic transplantation as immunotherapeutic approach.
Citations
Feb 18, 2011·Cancer Immunology, Immunotherapy : CII·Verena WiegeringBeate Winkler
Mar 23, 2011·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Toshihisa TsurutaYoshikazu Okada
Jun 16, 2005·Current Problems in Pediatric and Adolescent Health Care·Adam S Levy
Jul 29, 2006·Onkologie·Jaroslav SterbaPavel Mazanek
Jun 1, 2006·Expert Review of Neurotherapeutics·Melissa J SiegelStergios Zacharoulis
Jan 6, 2006·Pediatric Blood & Cancer·Giorgio Perilongo
Oct 18, 2007·Pediatric Blood & Cancer·L Mi Rim ChoiTobey J Macdonald
Feb 4, 2006·Pediatric Blood & Cancer·Halldora K ThorarinsdottirTobey J MacDonald
Dec 10, 2009·Pediatric Blood & Cancer·Stephen W GilheeneyIra J Dunkel
May 23, 2015·The Korean Journal of Internal Medicine·Jae-Ho YoonSeok-Goo Cho
Jul 3, 2015·Oncoimmunology·Junjie Wu, David J Waxman
Oct 4, 2017·Oncotarget·Moatasem El-AyadiAndre O von Bueren
Aug 7, 2020·Journal of Neuro-oncology·Adam J GrippinElias J Sayour
Oct 27, 2017·Brain Sciences·Elias J Sayour, Duane A Mitchell